SLNO
Soleno Therapeutics, Inc.
Price Chart
Latest Quote
$53.01
Current Price| Open | $52.98 |
| Day High | $53.01 |
| Day Low | $52.98 |
| Volume | 4,968,834 |
Stock Information
| Shares Outstanding | 52.12M |
| Total Debt | $54.28M |
| Cash Equivalents | $255.60M |
| Revenue | $285.01M |
| Net Income | $95.63M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.76B |
| P/E Ratio | 27.47 |
| EPS (TTM) | $1.93 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.56B |
| Sales | $285.01M |
| Income | $95.63M |
| Book/sh | $8.61 |
| Cash/sh | $4.90 |
| Employees | 182 |
Financial Ratios
| Quick Ratio | 5.21 |
| Current Ratio | 5.62 |
| Debt/Eq | 10.95 |
Returns & Margins
| ROA | 12.07% |
| ROE | 26.38% |
| Gross Margin | 98.63% |
| Operating Margin | 33.57% |
| Profit Margin | 33.70% |
Ownership
| Insider Ownership | 1.31% |
| Institutional Ownership | 111.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -23.35 |
| P/S | 9.69 |
| P/B | 6.16 |
Analyst Data
| Recommendation | hold |
| Target Price | $53.00 |
Technical Indicators
| SMA20 | $52.87 |
| SMA50 | $45.79 |
| SMA200 | $52.40 |
| RSI | 93.10 |
| ATR | 0.0507 |
| Shares Float | 51.46M |
| Short Float | 17.89% |
| Short Ratio | 1.01 |
| Volatility | -2.22 |
Performance History
| Week | +0.13% |
| Month | +0.44% |
| Quarter | +37.69% |
| 6 Months | +11.95% |
| YTD | +12.38% |
| Year | -29.39% |
| 3 Years | +1162.14% |
| 5 Years | +236.57% |
| 10 Years | -43.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-05-18 | $53.01 | 0 |
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
đ° Latest News
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus
Simply Wall St. âĸ 2026-05-11T03:14:09Z
Neurocrine Biosciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T01:35:48Z
Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal
Insider Monkey âĸ 2026-05-01T14:46:11Z
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
Zacks âĸ 2026-04-08T15:23:00Z
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story
Simply Wall St. âĸ 2026-04-07T14:08:08Z
Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-04-07T13:47:09Z
Company News for Apr 7, 2026
Zacks âĸ 2026-04-07T13:33:00ZSoleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger
Insider Monkey âĸ 2026-04-07T07:15:38Z
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Motley Fool âĸ 2026-04-06T21:40:08Z
Why Soleno Therapeutics Stock Rocketed Higher on Monday
Motley Fool âĸ 2026-04-06T20:40:38Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,700,000 | $0 | $0 | - |
| Cost Of Revenue | $2,700,000 | $0 | $0 | - |
| Total Revenue | $190,405,000 | $0 | $0 | $0 |
| Operating Revenue | $190,405,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $5,476,000 | $231,000 | $0 | $0 |
| Total Expenses | $175,455,000 | $184,429,000 | $38,670,000 | $25,109,000 |
| Other Income Expense | $-5,536,000 | $-3,242,000 | $-2,896,000 | $742,000 |
| Net Non Operating Interest Income Expense | $11,476,000 | $11,821,000 | $2,578,000 | $300,000 |
| Interest Expense Non Operating | $5,476,000 | $231,000 | $0 | $0 |
| Operating Expense | $172,755,000 | $184,429,000 | $38,670,000 | $25,109,000 |
| General And Administrative Expense | - | $105,861,000 | $13,481,000 | $9,844,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $20,890,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Net Interest Income | $11,476,000 | $11,821,000 | $2,578,000 | $300,000 |
| Interest Income | $16,952,000 | $12,052,000 | $2,578,000 | $300,000 |
| Normalized Income | $26,426,000 | $-172,608,000 | $-36,092,000 | $-24,809,000 |
| Net Income From Continuing And Discontinued Operation | $20,890,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Total Operating Income As Reported | $9,414,000 | $-187,671,000 | $-41,384,000 | $-24,397,000 |
| Net Income Common Stockholders | $20,475,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Net Income | $20,890,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Net Income Including Noncontrolling Interests | $20,890,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Net Income Continuous Operations | $20,890,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Pretax Income | $20,890,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Special Income Charges | $-5,536,000 | $-3,242,000 | $-2,714,000 | $712,000 |
| Interest Income Non Operating | $16,952,000 | $12,052,000 | $2,578,000 | $300,000 |
| Operating Income | $14,950,000 | $-184,429,000 | $-38,670,000 | $-25,109,000 |
| Gross Profit | $187,705,000 | $0 | $0 | - |
| Per Share | ||||
| Diluted EPS | $0.39 | $-4.38 | $-2.36 | $-2.87 |
| Basic EPS | $0.40 | $-4.38 | $-2.36 | $-2.87 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $33,919,000 | $-170,390,000 | $-34,134,000 | $-22,845,000 |
| Total Unusual Items | $-5,536,000 | $-3,242,000 | $-2,896,000 | $742,000 |
| Total Unusual Items Excluding Goodwill | $-5,536,000 | $-3,242,000 | $-2,896,000 | $742,000 |
| Reconciled Depreciation | $2,017,000 | $1,987,000 | $1,958,000 | $1,964,000 |
| EBITDA (Bullshit earnings) | $28,383,000 | $-173,632,000 | $-37,030,000 | $-22,103,000 |
| EBIT | $26,366,000 | $-175,619,000 | $-38,988,000 | $-24,067,000 |
| Diluted Average Shares | $52,384,886 | $40,175,926 | $16,492,132 | $8,397,088 |
| Basic Average Shares | $50,817,586 | $40,175,926 | $16,492,132 | $8,397,088 |
| Diluted NI Availto Com Stockholders | $20,475,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Otherunder Preferred Stock Dividend | $415,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $5,536,000 | $3,242,000 | $2,714,000 | $-712,000 |
| Research And Development | $40,627,000 | $78,568,000 | $25,189,000 | $15,265,000 |
| Selling General And Administration | $132,128,000 | $105,861,000 | $13,481,000 | $9,844,000 |
| Other Gand A | - | $105,861,000 | $13,481,000 | $9,844,000 |
| Gain On Sale Of Security | - | - | $-182,000 | $30,000 |
Fetched: 2026-05-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $445,254,000 | $238,308,000 | $148,758,000 | $-345,000 |
| Total Assets | $563,830,000 | $330,972,000 | $180,691,000 | $26,497,000 |
| Total Non Current Assets | $208,016,000 | $37,083,000 | $9,333,000 | $10,850,000 |
| Other Non Current Assets | $163,000 | $83,000 | $165,000 | - |
| Investmentin Financial Assets | $200,616,000 | $27,211,000 | $0 | - |
| Goodwill And Other Intangible Assets | $4,861,000 | $6,805,000 | $8,749,000 | $10,693,000 |
| Other Intangible Assets | $4,861,000 | $6,805,000 | $8,749,000 | $10,693,000 |
| Current Assets | $355,814,000 | $293,889,000 | $171,358,000 | $15,647,000 |
| Other Current Assets | $7,110,000 | $2,452,000 | $1,677,000 | $1,045,000 |
| Inventory | $15,024,000 | $0 | - | - |
| Receivables | $28,208,000 | $0 | - | - |
| Accounts Receivable | $28,208,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $305,472,000 | $291,437,000 | $169,681,000 | $14,602,000 |
| Cash And Cash Equivalents | $70,106,000 | $87,928,000 | $169,681,000 | $14,602,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $52,553,000 | $52,826,000 | $403,000 | $155,000 |
| Long Term Debt And Capital Lease Obligation | $51,827,000 | $52,300,000 | $130,000 | $0 |
| Long Term Debt | $49,863,000 | $49,828,000 | - | - |
| Current Debt And Capital Lease Obligation | $726,000 | $526,000 | $273,000 | $155,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $113,715,000 | $85,859,000 | $23,184,000 | $16,149,000 |
| Total Non Current Liabilities Net Minority Interest | $52,352,000 | $67,112,000 | $11,679,000 | $8,836,000 |
| Other Non Current Liabilities | $525,000 | $14,812,000 | $11,549,000 | $8,835,000 |
| Current Liabilities | $61,363,000 | $18,747,000 | $11,505,000 | $7,313,000 |
| Other Current Liabilities | $20,380,000 | $2,737,000 | $1,555,000 | $484,000 |
| Payables And Accrued Expenses | $16,549,000 | $13,445,000 | $6,542,000 | $4,999,000 |
| Interest Payable | $403,000 | $0 | - | - |
| Payables | $12,435,000 | $8,882,000 | $3,149,000 | $1,777,000 |
| Accounts Payable | $12,435,000 | $8,882,000 | $3,149,000 | $1,777,000 |
| Derivative Product Liabilities | - | - | $0 | $1,000 |
| Equity | ||||
| Common Stock Equity | $450,115,000 | $245,113,000 | $157,507,000 | $10,348,000 |
| Total Equity Gross Minority Interest | $450,115,000 | $245,113,000 | $157,507,000 | $10,348,000 |
| Stockholders Equity | $450,115,000 | $245,113,000 | $157,507,000 | $10,348,000 |
| Gains Losses Not Affecting Retained Earnings | $415,000 | $361,000 | $0 | - |
| Other Equity Adjustments | $415,000 | $361,000 | - | - |
| Retained Earnings | $-431,370,000 | $-452,260,000 | $-276,410,000 | $-237,422,000 |
| Other | ||||
| Ordinary Shares Number | $52,286,881 | $45,703,811 | $31,678,159 | $8,159,382 |
| Share Issued | $52,286,881 | $45,703,811 | $31,678,159 | $8,159,382 |
| Tangible Book Value | $445,254,000 | $238,308,000 | $148,758,000 | $-345,000 |
| Invested Capital | $499,978,000 | $294,941,000 | $157,507,000 | $10,348,000 |
| Working Capital | $294,451,000 | $275,142,000 | $159,853,000 | $8,334,000 |
| Capital Lease Obligations | $2,690,000 | $2,998,000 | $403,000 | $155,000 |
| Total Capitalization | $499,978,000 | $294,941,000 | $157,507,000 | $10,348,000 |
| Additional Paid In Capital | $881,018,000 | $696,966,000 | $433,885,000 | $247,762,000 |
| Capital Stock | $52,000 | $46,000 | $32,000 | $8,000 |
| Common Stock | $52,000 | $46,000 | $32,000 | $8,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,964,000 | $2,472,000 | $130,000 | $0 |
| Current Capital Lease Obligation | $726,000 | $526,000 | $273,000 | $155,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,677,000 | $4,776,000 | $3,135,000 | $1,675,000 |
| Current Provisions | $14,031,000 | - | - | - |
| Current Accrued Expenses | $4,114,000 | $4,563,000 | $3,393,000 | $3,222,000 |
| Investments And Advances | $200,616,000 | $27,211,000 | $0 | - |
| Available For Sale Securities | $200,616,000 | $27,211,000 | - | - |
| Net PPE | $2,376,000 | $2,984,000 | $419,000 | $157,000 |
| Accumulated Depreciation | $-123,000 | $-70,000 | $-89,000 | $-75,000 |
| Gross PPE | $2,499,000 | $3,054,000 | $508,000 | $232,000 |
| Leases | $93,000 | $52,000 | $0 | - |
| Other Properties | $2,191,000 | $2,798,000 | $407,000 | $131,000 |
| Machinery Furniture Equipment | $215,000 | $204,000 | $101,000 | $101,000 |
| Properties | $0 | $0 | $0 | - |
| Inventories Adjustments Allowances | $-157,000 | $0 | - | - |
| Finished Goods | $6,022,000 | $0 | - | - |
| Work In Process | $2,710,000 | $0 | - | - |
| Raw Materials | $6,449,000 | $0 | - | - |
| Other Short Term Investments | $235,366,000 | $203,509,000 | $0 | - |
Fetched: 2026-05-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $46,725,000 | $-69,314,000 | $-24,940,000 | $-20,794,000 |
| Operating Activities | ||||
| Operating Cash Flow | $46,798,000 | $-69,096,000 | $-24,940,000 | $-20,781,000 |
| Cash Flow From Continuing Operating Activities | $46,798,000 | $-69,096,000 | $-24,940,000 | $-20,781,000 |
| Operating Gains Losses | - | - | $182,000 | $-30,000 |
| Investing Activities | ||||
| Capital Expenditure | $-73,000 | $-218,000 | - | $-13,000 |
| Investing Cash Flow | $-201,781,000 | $-225,682,000 | $0 | $-13,000 |
| Cash Flow From Continuing Investing Activities | $-201,781,000 | $-225,682,000 | $0 | $-13,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-100,146,000 | $0 | $0 | - |
| Issuance Of Capital Stock | $215,721,000 | $148,955,000 | $137,857,000 | $14,108,000 |
| Financing Cash Flow | $137,161,000 | $213,025,000 | $180,019,000 | $14,092,000 |
| Cash Flow From Continuing Financing Activities | $137,161,000 | $213,025,000 | $180,019,000 | $14,092,000 |
| Net Other Financing Charges | $-803,000 | - | - | $-16,000 |
| Net Common Stock Issuance | $115,575,000 | $148,955,000 | $137,857,000 | $14,108,000 |
| Common Stock Issuance | $215,721,000 | $148,955,000 | $137,857,000 | $14,108,000 |
| Other | ||||
| Issuance Of Debt | $0 | $49,888,000 | $0 | $0 |
| Interest Paid Supplemental Data | $4,534,000 | $209,000 | $0 | - |
| End Cash Position | $70,106,000 | $87,928,000 | $169,681,000 | $14,602,000 |
| Beginning Cash Position | $87,928,000 | $169,681,000 | $14,602,000 | $21,304,000 |
| Changes In Cash | $-17,822,000 | $-81,753,000 | $155,079,000 | $-6,702,000 |
| Proceeds From Stock Option Exercised | $22,389,000 | $14,182,000 | $42,162,000 | $0 |
| Common Stock Payments | $-100,146,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $0 | $49,888,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $49,888,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $49,888,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-201,708,000 | $-225,464,000 | $0 | $0 |
| Sale Of Investment | $254,068,000 | $131,000,000 | $0 | $0 |
| Purchase Of Investment | $-455,776,000 | $-356,464,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-73,000 | $-218,000 | $0 | $-13,000 |
| Purchase Of PPE | $-73,000 | $-218,000 | $0 | $-13,000 |
| Change In Working Capital | $-24,633,000 | $6,018,000 | $2,928,000 | $-756,000 |
| Change In Other Current Liabilities | $13,831,000 | $-545,000 | $933,000 | $-141,000 |
| Change In Payables And Accrued Expense | $8,513,000 | $7,313,000 | $2,832,000 | $-728,000 |
| Change In Accrued Expense | $4,901,000 | $1,641,000 | $1,460,000 | $749,000 |
| Change In Payable | $3,612,000 | $5,672,000 | $1,372,000 | $-1,477,000 |
| Change In Account Payable | $3,612,000 | $5,672,000 | $1,372,000 | $-1,477,000 |
| Change In Prepaid Assets | $-4,738,000 | $-750,000 | $-837,000 | $113,000 |
| Change In Inventory | $-14,031,000 | $0 | $0 | - |
| Change In Receivables | $-28,208,000 | $0 | $0 | - |
| Changes In Account Receivables | $-28,208,000 | $0 | $0 | - |
| Other Non Cash Items | $6,195,000 | $3,686,000 | $3,035,000 | $-422,000 |
| Stock Based Compensation | $45,846,000 | $99,958,000 | $5,945,000 | $2,530,000 |
| Amortization Of Securities | $-3,517,000 | $-4,895,000 | $0 | $0 |
| Depreciation Amortization Depletion | $2,017,000 | $1,987,000 | $1,958,000 | $1,964,000 |
| Depreciation And Amortization | $2,017,000 | $1,987,000 | $1,958,000 | $1,964,000 |
| Net Income From Continuing Operations | $20,890,000 | $-175,850,000 | $-38,988,000 | $-24,067,000 |
| Change In Other Working Capital | - | - | $1,460,000 | $947,000 |
| Gain Loss On Investment Securities | - | - | $182,000 | $-30,000 |
| Repayment Of Debt | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
Fetched: 2026-05-18